In-vivo IE II: Imaginal Exposure II Study: In-Vivo

Sponsor
University of Louisville (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03934697
Collaborator
(none)
50
1
1
64
0.8

Study Details

Study Description

Brief Summary

The purpose of this study is to test if imaginal exposure therapy can decrease symptoms of eating disorders and anxiety.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: imaginal exposure therapy
N/A

Detailed Description

An initial meeting consisting of a screening, questionnaires, and a brief psychoeducation on imaginal exposure therapy, followed by 8-10 sessions with a licensed psychologist (the PI) or a clinical psychology graduate student who is supervised and trained by the PI. In Session 1, patients will create a script with the therapist on an eating disorder fear. In sessions 2-10 the therapist and patient will then imagine this eating disorder related fear based on the script. Each session will be modified to focus on "hot spots" or the most feared aspect of the script. Sessions will be audiotaped and videotaped and participants will be asked to listen to the sessions nightly for homework. Sessions will be weekly or twice per week for 8-10 weeks after the initial screening session.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
In-Vivo Treatment for Imaginal Exposure Therapy
Actual Study Start Date :
May 1, 2017
Actual Primary Completion Date :
Dec 13, 2020
Anticipated Study Completion Date :
Sep 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Imaginal Exposure Session

All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.

Behavioral: imaginal exposure therapy
All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
Other Names:
  • Exposure Therapy
  • Outcome Measures

    Primary Outcome Measures

    1. EDEQ (Eating Disorder Examination Questionnaire) at 1-10 Weeks and at 1 year [1 year and 10 weeks]

      The EDE-Q is a 41-item self-report questionnaire version of the Eating Disorder Examination, which is a semi-structured interview designed to assess eating disorders symptom frequency and severity over the past 28 days. The EDE-Q uses a 7-point forced-choice rating scheme (No days; 1-5 days; 6-12 days; 13-15 days; 16-22 days; 23-27 days; Everyday). The EDE-Q has four subscales with the question stem "How many days out of the past 28 days...": Restraint (e.g. Have you been consciously trying to restrict the amount of food you eat to influence your shape or weight?), Eating Concern (e.g. Have you had a definite fear that you might not be able to either resist eating or stop eating?), Weight Concern (e.g. Has your weight influenced how you think about (judge) yourself as a person?), and Shape Concern (e.g. How dissatisfied have you felt about your shape?).

    2. SUDS (Subjective Units of Distress Scale) at 1-10 Weeks and at 1 year [1 year and 10 weeks]

      The SUDS scale is a self-report behavioral measure used during exposure treatment and behavioral assessment to measure anxiety. The SUDS scale has been shown to be a valid and reliable measure of state anxiety. SUDS ratings can range from 0 (completely calm) to 100 (highest anxiety). Other reference points used in this study include 25 (noticeable, but not bothersome anxiety), 50 (bothersome anxiety), and 75 (very bothersome anxiety). Subjective anxiety was assessed both in terms of categorical response and overall change. Categorical response was defined as a drop of at least five points in average SUDS across the exposure across visits.

    3. Body Mass Index (BMI) at 1-10 Weeks and at 1 year [1 year and 10 weeks]

      Participants will be weighed at 1-10 Weeks and at 1 year and BMI will be calculated in order to see if the BMI of an individual has changed over time.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Must be at least 18 years of age (no age limit)

    • Must currently meet criteria for anorexia, sub-clinical anorexia, bulimia, or sub-clinical bulimia (using the eating disorder diagnostic scale), OR have met criteria for one of these eating disorders in the last year, OR endorse significant eating disorder fears

    • Must have at least one significant eating disorder related fear.

    Exclusion Criteria:
    • Under 18 years of age

    • Individuals who have binge eating disorder or an unspecified eating disorder, OR who do not meet eating disorder related criteria

    • Individuals who meet criteria for mania, psychosis, or suicidal ideation

    • Participants who are not able to secure transportation to complete therapy sessions

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Eating Anxiety Treatment Laboratory and Clinic Louisville Kentucky United States 40205-1016

    Sponsors and Collaborators

    • University of Louisville

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Cheri Levinson, Asst Professor, University of Louisville
    ClinicalTrials.gov Identifier:
    NCT03934697
    Other Study ID Numbers:
    • IRB#:16.1003
    First Posted:
    May 2, 2019
    Last Update Posted:
    Nov 23, 2021
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Cheri Levinson, Asst Professor, University of Louisville
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 23, 2021